SCHEMBL15066977

SCHEMBL15066977

Cc1ccc2c(Oc3ccccc3)nccc2c1NC(=O)c1csc2c(N)ncnc12

nearest known ligand 0.65

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
BRAF P15056 12/20 0.65
RAF1 P04049 10/20 0.65
CSF1R P07333 13/20 0.62
DDR2 Q16832 6/20 0.62
DDR1 Q08345 5/20 0.62
ARAF P10398 1/20 0.59
FGFR1 P11362 1/20 0.40
KDR P35968 1/20 0.40
TEK Q02763 1/20 0.40
MELK Q14680 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15066865 0.87 BRAF (0.84) BRAFRAF1CSF1RDDR2DDR1
SCHEMBL21387840 0.85 BRAF (0.72) BRAFRAF1CSF1RDDR2DDR1
SCHEMBL24399594 0.85 BRAF (0.65) BRAFRAF1CSF1RDDR2DDR1
SCHEMBL29638595 0.85 BRAF (0.65) BRAFRAF1CSF1RDDR2DDR1
SCHEMBL31406752 0.83 BRAF (0.84) BRAFRAF1CSF1RDDR2DDR1
SCHEMBL15067359 0.83 BRAF (0.84) BRAFRAF1CSF1RDDR2DDR1
SCHEMBL22467862 0.82 BRAF (0.74) BRAFRAF1CSF1RDDR2DDR1
SCHEMBL30566307 0.82 BRAF (0.74) BRAFRAF1CSF1RDDR2DDR1
SCHEMBL15067020 0.81 BRAF (0.67) BRAFRAF1CSF1RDDR2DDR1
SCHEMBL24399552 0.79 BRAF (0.66) BRAFRAF1CSF1RDDR2DDR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2797927-B1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES HANMI PHARM IND CO LTD (KR) 2019-09-25 EP claimed
US-RE47451-E1 Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases HANMI PHARM. CO. LTD. (KR) 2019-06-25 US claimed
US-9156852-B2 Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases HANMI PHARM. CO., LTD (KR) 2015-10-13 US claimed
US-20140371219-A1 THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES HANMI PHARM. CO., LTD (KR) 2014-12-18 US claimed
EP-2797927-A1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES Hanmi Pharm. Co., Ltd. (KR) 2014-11-05 EP claimed
WO-2013100632-A1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES HANMI PHARM CO., LTD. (KR) 2013-07-04 WO claimed
EP-3617213-B1 THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES HANMI PHARMACEUTICAL CO LTD (KR) 2025-02-19 EP disclosed
EP-3617213-A1 THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES Hanmi Pharm. Co., Ltd. (KR) 2020-03-04 EP disclosed
EP-2797927-B1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES HANMI PHARM IND CO LTD (KR) 2019-09-25 EP disclosed
US-RE47451-E1 Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases HANMI PHARM. CO. LTD. (KR) 2019-06-25 US disclosed
US-RE47451-E1 Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases HANMI PHARM. CO. LTD. (KR) 2019-06-25 US disclosed
US-9156852-B2 Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases HANMI PHARM. CO., LTD (KR) 2015-10-13 US disclosed
US-9156852-B2 Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases HANMI PHARM. CO., LTD (KR) 2015-10-13 US disclosed
US-9156852-B2 Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases HANMI PHARM. CO., LTD (KR) 2015-10-13 US disclosed
US-20140371219-A1 THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES HANMI PHARM. CO., LTD (KR) 2014-12-18 US disclosed
US-20140371219-A1 THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES HANMI PHARM. CO., LTD (KR) 2014-12-18 US disclosed
US-20140371219-A1 THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES HANMI PHARM. CO., LTD (KR) 2014-12-18 US disclosed
EP-2797927-A1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES Hanmi Pharm. Co., Ltd. (KR) 2014-11-05 EP disclosed
WO-2013100632-A1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES HANMI PHARM CO., LTD. (KR) 2013-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371219-A1 THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES TK1, DTYMK, MAP4K2 BRAF 190/4885RAF1 148/4885CSF1R 3310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.